Form 8-K - Current report:
SEC Accession No. 0001213900-25-036363
Filing Date
2025-04-29
Accepted
2025-04-29 07:05:35
Documents
13
Period of Report
2025-04-29
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0239804-8k_moonlake.htm   iXBRL 8-K 23797
  Complete submission text file 0001213900-25-036363.txt   194770

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE mltx-20250429.xsd EX-101.SCH 3020
3 XBRL LABEL FILE mltx-20250429_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE mltx-20250429_pre.xml EX-101.PRE 22362
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0239804-8k_moonlake_htm.xml XML 3551
Mailing Address DORFSTRASSE 29 ZUG V8 6300
Business Address DORFSTRASSE 29 ZUG V8 6300 41 41 510 8022
MoonLake Immunotherapeutics (Filer) CIK: 0001821586 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39630 | Film No.: 25882618
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)